Replies to post #136707 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Anavex's (AVXL) CEO Christopher Missling on Q4 2017 Results - Earnings Call (Transcript)

We recently filed an IND for ANAVEX 2-73 in Rett syndrome, and we are currently expecting feedback from the FDA to finalize the clinical trial protocol for this study, which will be a 12-week randomized double-blind placebo controlled study. As start-up activities with clinical trial sites have been underway, we anticipate dosing of the first patient in due course following FDA approval of the IND.

[LakeshoreLeo1953]

Anavex is NOT going to run the trials.

Hopefully their selection of CRO to conduct the study
will be reputable and competent so that the review of
the data when available is timely.

In that sense evaluating three trials data at completion at once
would be a challenge given the size of the Company.